- Home
- ELA vs CHRS Comparison
ELA vs CHRS Comparison
Compare ELA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELA
- CHRS
- Stock Information
- Founded
- ELA 1965
- CHRS 2010
- Country
- ELA United States
- CHRS United States
- Employees
- ELA N/A
- CHRS N/A
- Industry
- ELA Consumer Specialties
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELA Consumer Discretionary
- CHRS Health Care
- Exchange
- ELA Nasdaq
- CHRS Nasdaq
- Market Cap
- ELA 190.2M
- CHRS 191.3M
- IPO Year
- ELA N/A
- CHRS 2014
- Fundamental
- Price
- ELA $7.07
- CHRS $1.42
- Analyst Decision
- ELA Strong Buy
- CHRS Strong Buy
- Analyst Count
- ELA 1
- CHRS 4
- Target Price
- ELA $7.00
- CHRS $5.38
- AVG Volume (30 Days)
- ELA 18.5K
- CHRS 2.1M
- Earning Date
- ELA 11-05-2024
- CHRS 03-12-2025
- Dividend Yield
- ELA N/A
- CHRS N/A
- EPS Growth
- ELA N/A
- CHRS N/A
- EPS
- ELA 0.25
- CHRS N/A
- Revenue
- ELA $165,946,534.00
- CHRS $304,340,000.00
- Revenue This Year
- ELA $1.61
- CHRS $2.47
- Revenue Next Year
- ELA $6.30
- CHRS N/A
- P/E Ratio
- ELA $27.54
- CHRS N/A
- Revenue Growth
- ELA N/A
- CHRS 44.19
- 52 Week Low
- ELA $4.15
- CHRS $0.66
- 52 Week High
- ELA $7.88
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- ELA 50.59
- CHRS 47.64
- Support Level
- ELA $6.57
- CHRS $1.44
- Resistance Level
- ELA $7.21
- CHRS $1.60
- Average True Range (ATR)
- ELA 0.28
- CHRS 0.13
- MACD
- ELA -0.08
- CHRS -0.03
- Stochastic Oscillator
- ELA 54.95
- CHRS 16.67
About ELA Envela Corporation
Envela Corp and its subsidiaries engage in diverse business activities within the recommerce sector. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.